MedTrace Logo

Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

NCT02743078 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2021-06-02

Study results available
· View outcomes & findings →

Summary

This phase II trial will investigate the efficacy and safety of the addition of Optune (Tumor Treating Fields \[TTFields\] Therapy) to bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma.

Conditions

Interventions

DRUG

Bevacizumab

10 mg/kg every 2 weeks intravenously over 30 minutes.

DEVICE

TTFields Therapy

Device is worn continuously at least 18 hours a day on average, with 1-3 days off every four weeks.

Sponsors & Collaborators

  • NovoCure Ltd.

    collaborator INDUSTRY

  • RTOG Foundation, Inc.

    lead OTHER

Principal Investigators

  • Manmeet Ahluwalia, MD, FACP · RTOG Foundation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-09
Primary Completion
2019-10-15
Completion
2019-10-15
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02743078 on ClinicalTrials.gov